Compliance
RSSArticles
-
Botched Open-heart Surgery Results in $68 Million Verdict
The lawsuit alleged the surgeon left the room during open-heart surgery, leaving the patient still bleeding.
-
Healthcare Slow to Patch Software, Creating Vulnerability
The healthcare and pharmaceutical industries are not adequately patching software, leaving their systems vulnerable to attack, according to a recent survey conducted by the Ponemon Institute.
-
Resources for Reducing Workplace Violence Injuries
There are many resources risk managers can use when implementing a comprehensive workplace violence program in a healthcare facility.
-
Good Reporting, Data Usage Can Curb Workplace Violence
The Joint Commission recommends seven steps to address violence in healthcare settings.
-
Higher Risk of Workplace Violence in Healthcare Requires Attention
Workplace violence is a serious problem in the healthcare industry. Three-fourths of all workplace violence occurs in a healthcare or social service setting.
-
Physician Injuries Can Create Even Higher Workers’ Comp Costs
Workers’ comp injuries in healthcare most commonly affect nurses and aides, who are more often involved with high-risk activities like moving patients, but physicians also can be injured on the job.
-
Minimize Workers’ Compensation Costs With the Right Approach
Workers’ compensation claims are a major concern for healthcare risk managers and can create tremendous liability for the healthcare organization, but careful attention to injury prevention and proper handling of claims can keep the costs to a minimum.
-
Prince Lawsuit Shows Risks of ‘Star Treatment’ for Celebrity Patients
Celebrity status can lead healthcare providers to change the standard of care, often unwittingly.
-
Correction
The March issue of IRB Advisor featured a story about plain language informed consent with an incorrect reference.
-
FDA Moves to Shutter Stem Cell Clinics
The FDA recently filed complaints in federal court seeking “permanent injunctions to stop two stem cell clinics from marketing stem cell products without FDA approval and for significant deviations from current good manufacturing practice requirements.”